Keyphrases
Phase II Study
100%
Delafloxacin
100%
Moxifloxacin
100%
Community-acquired Bacterial Pneumonia
100%
Test of Cure
22%
Early Clinical Response
22%
Response Rate
11%
United States
11%
Randomized Double-blind
11%
Success Rate
11%
Global Phase
11%
Monotherapy
11%
Twice Daily
11%
Clinical Response
11%
Between-group
11%
Intent-to-treat Analysis
11%
Treatment-related Adverse Events
11%
First Dose
11%
Once-daily
11%
Population Aging
11%
Gram-negative Pathogens
11%
Economic Burden
11%
Treatment Burden
11%
Non-inferiority
11%
Gram-positive
11%
Spectrum of Activity
11%
Side Effect Profile
11%
Fluoroquinolone Antibiotics
11%
Skin Structure Infections
11%
Acute Bacterial Skin
11%
Charging Profile
11%
Atypical Pathogens
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bacterial Pneumonia
100%
Delafloxacin
100%
Moxifloxacin
100%
Infectious Agent
22%
Infection
11%
Monotherapy
11%
Adverse Event
11%
Side Effect
11%
Quinoline Derived Antiinfective Agent
11%